BioXcel Therapeutics Announces Journal of the American Medical Association Publication of Data from SERENITY II Pivotal Phase 3 Trial Evaluating BXCL501 in Bipolar Disorders
BXCL501 demonstrated statistically significant and clinically meaningful improvements in primary and key secondary efficacy measures…